Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922323 | 0.90 | CTSS (0.42) | CTSKCTSSSCN9APPARAPPARG | |
| SCHEMBL9963890 | 0.90 | CTSS (0.56) | CTSKCTSSSCN9ACTSBBCL2 | |
| SCHEMBL20734850 | 0.85 | CTSS (0.54) | CTSKCTSSSCN9ACTSBCTSL | |
| SCHEMBL22154195 | 0.85 | CTSS (0.54) | CTSKCTSSSCN9ACTSBCTSL | |
| SCHEMBL19573812 | 0.83 | CTSK (0.45) | CTSKCTSSSCN9APPARAPPARG | |
| SCHEMBL20113130 | 0.83 | CTSK (0.51) | CTSKCTSSSCN9APPARAPPARG | |
| SCHEMBL30186155 | 0.81 | CTSK (0.46) | CTSKCTSSIDO1CTSL | |
| SCHEMBL30186152 | 0.81 | CTSK (0.46) | CTSKCTSSIDO1CTSL | |
| SCHEMBL29105872 | 0.81 | CTSK (0.46) | CTSKCTSSIDO1CTSL | |
| SCHEMBL18597844 | 0.81 | CTSS (0.47) | CTSKCTSSSCN9ACTSBBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | CTSK 178/4885CTSS 117/4885SCN9A 596/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CTSK 178/4885CTSS 117/4885SCN9A 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.